



US009249214B2

(12) **United States Patent**
Jones et al.(10) **Patent No.:** US 9,249,214 B2
(45) **Date of Patent:** Feb. 2, 2016(54) **MONOCLONAL ANTIBODIES FOR EBOLA AND MARBURG VIRUSES**(71) Applicant: **Her Majesty the Queen in the Right of Canada as Represented by the Minister of Health**, Winnipeg (CA)(72) Inventors: **Steven Jones**, Winnipeg (CA); **Xiangguo Qiu**, Winnipeg (CA); **Heinz Feldmann**, Winnipeg (CA); **Ute Stroher**, Winnipeg (CA)(73) Assignee: **Her Majesty the Queen in the Right of Canada as Represented by the Minister of Health**, Winnipeg (CA)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **13/940,712**(22) Filed: **Jul. 12, 2013**(65) **Prior Publication Data**

US 2015/0344546 A1 Dec. 3, 2015

Related U.S. Application Data

(62) Division of application No. 12/864,584, filed as application No. PCT/CA2009/000070 on Jan. 27, 2009, now Pat. No. 8,513,391.

(60) Provisional application No. 61/025,491, filed on Feb. 1, 2008.

(51) **Int. Cl.****C07K 16/08** (2006.01)
C07K 16/10 (2006.01)(52) **U.S. Cl.**CPC **C07K 16/10** (2013.01); **C07K 2317/21** (2013.01); **C07K 2317/56** (2013.01); **C07K 2317/62** (2013.01)(58) **Field of Classification Search**
CPC C07K 16/00–16/468; C07K 16/08;
C07K 16/10
See application file for complete search history.(56) **References Cited**

U.S. PATENT DOCUMENTS

8,513,391 B2 * 8/2013 Jones C07K 16/10
424/130.1
2015/0232538 A1 * 8/2015 Jones C07K 16/10
424/133.1

FOREIGN PATENT DOCUMENTS

WO 2004018649 3/2004

OTHER PUBLICATIONS

Audet et al., Scientific Reports, 4:6881 (2014), DOI: 10.1038/srep06881.*

Takada, A. et al., "Protective Efficacy of Neutralizing Antibodies Against Ebola Virus Infection", Vaccine, 2007, vol. 25, pp. 993-999, ISSN: 0264-410X.

Shahhosseini, S. et al., "Production and characterization of monoclonal antibodies against different epitopes of Ebola virus antigens", Journal of Virological Methods, 2007, vol. 143, pp. 29-37, ISSN: 0166-0934.

* cited by examiner

Primary Examiner — Sheela J Huff*Assistant Examiner* — Jessica H Roark(74) *Attorney, Agent, or Firm* — Thomas E. Jurgensen; Optima Law Group, APC(57) **ABSTRACT**

Described herein are a number of Ebola monoclonal antibodies.

4 Claims, 4 Drawing Sheets




Fig. 1




Fig. 2




Fig. 3




Fig. 4

1

**MONOCLONAL ANTIBODIES FOR EBOLA
AND MARBURG VIRUSES**

PRIOR APPLICATION INFORMATION

The instant application is a divisional application of U.S. Ser. No. 12/864,584, filed Oct. 26, 2010, which was a 371 of PCT Application CA2009/000070, filed Jan. 27, 2009, now abandoned, which claims the benefit of U.S. Provisional Patent Application 61/025,491, filed Feb. 1, 2008.

BACKGROUND OF THE INVENTION

Ebola and Marburg viruses are highly pathogenic and virulent viruses causing rapidly fatal haemorrhagic fever in humans.

SUMMARY OF THE INVENTION

According to a first aspect of the invention, there is provided a monoclonal antibody comprising an amino acid sequence deduced from 1H3-light (SEQ ID No. 2); 2G4-light (SEQ ID No. 4); 4G7-light (SEQ ID No. 6); 5D2-light (SEQ ID No. 8); 5E6-light (SEQ ID No. 10); 7C9-light (SEQ ID No. 12); 7G4-light (SEQ ID No. 14), 10C8-light (SEQ ID No. 16), 1H3-heavy (SEQ ID No. 1); 2G4-heavy (SEQ ID No. 3); 4G7-heavy (SEQ ID No. 5); 5D2-heavy (SEQ ID No. 7), 5E6-heavy (SEQ ID No. 9), 7C9-heavy (SEQ ID No. 11), 7G4-heavy (SEQ ID No. 13) and 10C8-heavy (SEQ ID No. 15).

According to a second aspect of the invention, there is provided a method of preparing a chimeric antibody comprising:

providing an expression vector comprising a nucleic acid molecule encoding a constant region domain of a human light chain or heavy chain genetically linked to a nucleic acid encoding a light chain variable region selected from the group consisting of 1H3-light (SEQ ID No. 2); 2G4-light (SEQ ID No. 4); 4G7-light (SEQ ID No. 6); 5D2-light (SEQ ID No. 8); 5E6-light (SEQ ID No. 10); 7C9-light (SEQ ID No. 12); 7G4-light (SEQ ID No. 14) and 10C8-light (SEQ ID No. 16) or a heavy chain variable region selected from the group consisting of 1H3-heavy (SEQ ID No. 1); 2G4-heavy (SEQ ID No. 3); 4G7-heavy (SEQ ID No. 5); 5D2-heavy (SEQ ID No. 7), 5E6-heavy (SEQ ID No. 9), 7C9-heavy (SEQ ID No. 11), 7G4-heavy (SEQ ID No. 13) and 10C8-heavy (SEQ ID No. 15);

expressing the expression vector in a suitable host; and recovering the chimeric antibody from said host.

According to a third aspect of the invention, there is provided a method of preparing a recombinant antibodies comprising:

providing a nucleotide sequence selected from the group consisting of 1H3-light (SEQ ID No. 2); 2G4-light (SEQ ID No. 4); 4G7-light (SEQ ID No. 6); 5D2-light (SEQ ID No. 8); 5E6-light (SEQ ID No. 10); 7C9-light (SEQ ID No. 12); 7G4-light (SEQ ID No. 14), 10C8-light (SEQ ID No. 16), 1H3-heavy (SEQ ID No. 1); 2G4-heavy (SEQ ID No. 3); 4G7-heavy (SEQ ID No. 5); 5D2-heavy (SEQ ID No. 7), 5E6-heavy (SEQ ID No. 9), 7C9-heavy (SEQ ID No. 11), 7G4-heavy (SEQ ID No. 13) and 10C8-heavy (SEQ ID No. 15);

modifying said nucleic acid sequence such that at least one but fewer than about 30 of the amino acid residues encoded by said nucleic acid sequence has been changed or deleted without disrupting antigen binding of said peptide; and

2

expressing and recovering said modified nucleotide sequence.

BRIEF DESCRIPTION OF THE DRAWINGS

5

FIG. 1. Kaplan-Meier survival curve of mice infected with MA-ZEBOV and treated with MAbs 1 day after infection. Survival curve of MA-Ebola virus-infected mice treated with 100 µg of MAbs. Mice were intraperitoneally treated with 100 µg of each MAb on day 1. Control mice were given equal volumes of PBS.

FIG. 2. Weight changes of GPA-Ebola infected guinea pigs treated with MAbs. Weight changes of virus-infected guinea pigs treated with cocktail of MAbs. Guinea pigs were intraperitoneally treated with either 5D2, 5E6, 7C9, 7G4 or 10C8 (3 mg/treatment) on day 1 and 4G7+1H3+2G4 [(2 mg+1 mg+1 mg)/treatment] on day 2. Control guinea pig were given equal volume of PBS. The results are shown as the means and standard deviations of 6 guinea pigs.

FIG. 3. Weight changes of GPA-Ebola infected guinea pigs treated with MAbs. Weight changes of virus-infected guinea pigs treated with cocktail of MAbs. Guinea pigs were intraperitoneally treated with either 5D2, 5E6, 7C9, 7G4 or 10C8 (3 mg/treatment) on day 1 and 4G7+1 H3+2G4 [(2 mg+1 mg+1 mg)/treatment] on day 2. Control guinea pig were given equal volume of PBS. The results are shown as the group weight of 6 guinea pigs.

FIG. 4. Immunoprecipitation. 293T cells were transfected with pCAGGS-ZEbovGP1,2 by using Fugene 6. After 48 hrs, cells were collected and washed 2x with cold PBS before being lysed with 2x RIPA buffer. After clarifying the cell lysate, 100 µg protein was added to each McAb (5 µg) coupled protein A+G beads. The IP samples were run 10% SDS-PAGE and transferred to Hybond-P membrane. The blot was probed with mouse ant-EBOV-GP1.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned hereunder are incorporated herein by reference.

DEFINITIONS

As used herein, "neutralizing antibody" refers to an antibody, for example, a monoclonal antibody, capable of disrupting a formed viral particle or inhibiting formation of a viral particle or prevention of binding to or infection of mammalian cells by a viral particle.

As used herein, "diagnostic antibody" or "detection antibody" or "detecting antibody" refers to an antibody, for example, a monoclonal antibody, capable of detecting the presence of an antigenic target within a sample. As will be appreciated by one of skill in the art, such diagnostic antibodies preferably have high specificity for their antigenic target.

As used herein, "humanized antibodies" refer to antibodies with reduced immunogenicity in humans.

As used herein, "chimeric antibodies" refer to antibodies with reduced immunogenicity in humans built by genetically linking a non-human Variable region to human constant domains.

3

Described herein are a number of Ebola and Marburg monoclonal antibodies. Specifically, antigens were developed using a live replicating vector vesicular stomatitis virus described in PCT Application PCT/CA03/001125.

The VSV based vaccine delivery system was used to develop monoclonal antibodies in mice.

Specifically, described herein are monoclonal antibodies 1H3, 2G4, 4G7, 5D2, 5E6, 7C9, 7G4 and 10C8. As discussed below, 1H3 comprises 1H3-heavy chain (SEQ ID No. 1) and 1H3-light chain (SEQ ID No. 2); 2G4 comprises 2G4-heavy chain (SEQ ID No. 3) and 2G4-light chain (SEQ ID No. 4); 4G7 comprises 4G7-heavy chain (SEQ ID No. 5) and 4G7-light chain (SEQ ID No. 6); 5D2 comprises 5D2-heavy chain (SEQ ID No. 7) and 5D2-light chain (SEQ ID No. 8); 5E6 comprises 5E6-heavy chain (SEQ ID No. 9) and 5E6-light chain (SEQ ID No. 10); 7C9 comprises 7C9-heavy chain (SEQ ID No. 11) and 7C9-light chain (SEQ ID No. 12); 7G4 comprises 7G4-heavy chain (SEQ ID No. 13) and 7G4-light chain (SEQ ID No. 14); and 10C8 comprises 10C8-light chain (SEQ ID No. 15) and 10C8-heavy chain (SEQ ID No. 16).

These antibodies also appear to have high affinity and avidity to Ebola glycoproteins, which means that they could be used as highly sensitive diagnostic tools.

For example, as shown in FIG. 1, mice infected with MA-ZEBOV and subsequently treated with the monoclonal antibodies described above showed increased survival compared to mice treated with PBS. Results are summarized in Tables 1 and 2.

FIGS. 2 and 3 show weight changes in guinea pigs treated with the monoclonal antibodies or mixtures thereof post infection. As can be seen, guinea pigs treated with the monoclonal antibodies showed consistent weight while those treated with PBS showed significant weight loss. Results are summarized in Table 3.

The nucleotide sequences of the heavy and light chains of 1H3, 2G4, 4G7, 5D2, 5E6, 7C9, 7G4 and 10C8 follow. As will be appreciated by one of skill in the art, the amino acid sequences of these antibodies can easily be deduced from the nucleotide sequences. Accordingly, in some embodiments, the invention is directed to amino acid sequences deduced from 1H3-light (SEQ ID No. 2); 2G4-light (SEQ ID No. 4); 4G7-light (SEQ ID No. 6); 5D2-light (SEQ ID No. 8); 5E6-light (SEQ ID No. 10); 7C9-light (SEQ ID No. 12); 7G4-light (SEQ ID No. 14); 10C8-light (SEQ ID No. 16); 1H3-heavy (SEQ ID No. 1); 2G4-heavy (SEQ ID No. 3); 4G7-heavy (SEQ ID No. 5); 5D2-heavy (SEQ ID No. 7); 5E6-heavy (SEQ ID No. 9); 7C9-heavy (SEQ ID No. 11); 7G4-heavy (SEQ ID No. 13) and 10C8-heavy (SEQ ID No. 15).

mAb 1H3 heavy chain sequence: 373 bp

(SEQ ID No. 1)
TGGGGCAGAGCTTGTGAAGCCAGGGCCTCAGTCAGTTGCTCTGCACAG
CTTCTGGCTTCAACATTAAGACACCTATATACATTGGTGAACAGGGG
CCTGAAACAGGGCTGGAGTGGATTGGAAGGATTGATCCTCGCAATGGTAA
TACTAAATATGACCCGAAGTTCAGGGCAAGGCCACTATCACAGCAGACA
CATCCTCCAATACAGCCTACCTGCAGCTCAGCGGCTGACATCTGAGGAC
ACTGCCGTCTATTACTGTGCTAGGGAGTCGAGGATATCTACTATGCTTAC
GACGGGGTACTTGACTACTGGGCAAGGCACCACTCTCACAGTCTCCT
CAGCCAAAACACAGCCCCATCG

4

mAb 1H3 light chain sequence: 303 bp

(SEQ ID NO. 2)

5 GCAAATCATGTCCTGCATCTCCAGGGGAGAAGGTACCATGACCTGCAGTGC
CAGCTCAAGTGTAAAGTTACATGTACTGGTACCAGCAGAAGCCAGGATCCT
CCCCCAGACTCCTGATTATGACACATCCAACCTGGCTTCTGGAGTCCCT
10 GTTCGCTTCAGTGGCAGTGGCTGGGACCTTTACTCTCTCACAAATCAG
CCGAATGGAGGCTGAAGATGCTGCCACTTATTACTGCCAGCAGTGGAGTA
15 GTTACCCGTACACGTTGGAGGGGGACCAAGCTGGAAATAAACGGGCT
GAT

mAb 2G4 heavy chain sequence: 364 bp

20 (SEQ ID NO. 3)
TGGAGGAGGCTTGTATGCAACCTGGAGGATCATGAAACTCTCTGTGTTG
CCTCAGGATTCACTTCAGTAACACTGGATGAACTGGTCCGCCAGTCT
25 CCAGAGAAGGGGCTTGAGTGGTTGCTGAAATTAGATTGAACTAACTAA
TTATGCAACACATTATGCGGAGTCTGTGAAAGGGAGGTTACCATTTCAA
GAGATGATTCCAAAAGGAGTGTCTACCTGCAAATGAATACCTTAAGGCT
30 GAAGACACTGGCATTATTACTGTACCCGGGGAATGGTAACACTACAGGGC
TATGGACTACTGGGTCAAGGAACCTCAGTCACCGTCTCTCAGCCAAAA
CAACACCCCCATCA
35 mAb 2G4 light chain sequence: 306 bp

(SEQ ID NO. 4)

40 GCCTCCCTATCTGTATCTGTGGAGAAACTGTCTCCATCACATGTCGAGC
AAGTGAGAATATTACAGTAGTTAGCATGGTATCAGCAGAAACAGGGAA
AATCTCCTCAGCTCCTGGTCTATTCTGCAAACAACTTAGCAGATGGTGTG
45 CCATCAAGGTTCACTGGCAGTGGATCAGGCACTCAGTATTCCCTCAAGAT
CAACAGCCTGCAGTCTGAAGATTGGACTTATTACTGTCAACATTGTT
GGGGTACTCCGTACACGTTGGAGGGGGACCAAGCTGGAAATAACCGG
GCTGAT

50 mAb 4G7 heavy chain sequence: 358 bp

(SEQ ID NO. 5)

TGGACCTGAGCTGGAGATGCCCTGGCGCTTCAGTGAAGATACTCTGCAAGG
55 CTTCTGGTTCTCATTACTGGCTTCAGTATGAACTGGGTGAAGCAGAGC
AATGGAAAGAGCCTTGAGTGGATTGGAAATTGATACTTATTATGGTGG
TACTACCTACAACCAGAAATTCAAGGGCAAGGCCACATTGACTGTGGACA
60 AATCCTCAGCAGCCTACATGCAGCTCAAGAGCCTGACATCTGAGGAC
TCTGCAGTCTATTACTGTGCAAGATGGCTACTACGGTAGTACTTTGC
TTACTGGGCAAGGGACTCTGGTACTGTCTCTGCAAGCCAAAACACAG
65 CCCCCATCG

US 9,249,214 B2

5

mAb 4G7 light chain sequence: 306 bp

(SEQ ID No. 6)
 GCCTCCCTATCTGCATCTGTGGAGAAACTGTCACCATCACATGTGAGC
 AAGTGAGAATATTTACAGTTATTAGCATGGTATCAGCAGAACAGGGAA
 AATCTCCTCAGCTCCTGGTCTATAATGCCAAAACCTTAATAGAGGGTGT
 CCATCAAGGTTAGTGGCAGTGGATCAGGCACACAGTTCTGAAGAT
 CAACAGCCTGCAGCCTGAAGATTTGGGAGTTATTCTGTCAACATCATT
 TTGGTACTCCATTACACATTGGCTCGGGACAGAGTTGGAAATAAACGG
 GCTGAT

mAb 5D2 heavy chain sequence: 340 bp

(SEQ ID No. 7)
 GGGACCTGGCTGGTGAGACCTCTCAGTCTCTGCCCTCACCTGCACTG
 TCACTGGCTACTCAATCACCACTGATTATGCCCTGGAACTGGATCCGGCAG
 TTCCAGGAAACAAACTGGAGTGGCTGGCTATATAACCAACACTGGTAG
 CACTGGCTCAACCCATCTCTCAAAGTCGAATCTCTATCACTCGAGACA
 CATCCAAGAACCACTGTTCTCTGCAGTTGATTCTGTGACTACTGAGGAG
 ACAGCCACATATCACTGTGCAAGGGCCTTGCTTACTGGGCCAAGGGAC
 TCTGGTCACTGTCTCTGCAGC AAAACACAGCCCCATCG

mAb 5D2 light chain sequence: 321 bp

(SEQ ID No. 8)
 CTCACTTTGTCGTTACCATTGGACAACCCAGCCTCCATCTCTGCAAGTC
 AAGTCAGAGCCTCTAGATAGTGTGAGAACATATCTGAATTGGTTGT
 TACAGAGGCCAGGCCAGTCTCAAAGGCCATAATCTATCTGGTGTCTAAA
 CTGGACTCTGGAGTCACTGACAGGTTACTGGCAGTGGATCAGGGACAGA
 TTCACACTGAAAATCAGCAGAGTGGAGGCTGAGGATTGGGAGTTATT
 ATTGTTGGCAAGGTACACACTCTCCATTCACTTCCGGCTGGGACAAAG
 TTGGAAAATAAACAGGGCTGAT

mAb 5E6 heavy chain sequence: 370 bp

(SEQ ID No. 9)
 TGGGGGAGGCTTAGTGAAGCCTGGAGGGTCCCCTGAAACTCTCCGTGAG
 CCTCTGGATCCGCTTCACTGAGATATGACATGTCTGGGTCGCCAGACT
 CGGGAGAAGAGGCTGGAGTGGTCGCATACATTAGTCGTGGGGTGGTT
 CATCTACTATCCAGACACTGTGAAGGGCCGATTCAACATCTCCAGAGACA
 ATGCCAAGAACCCCTGTACCTGCAAATGAGCAGTCTGAAGTCTGACGAC
 ACAGCCATGTATTACTGTGCAAGACACGTTACTACGGTAGTAGCCCCCT
 CTATGCTATGGACTACTGGGTCAGGAAACCTCAGTCACCGCTCCTCAG
 CCAAAACAAACAGCCCCATCG

6

mAb 5E6 light chain sequence: 324 bp

(SEQ ID No. 10)
 5 TCAGCCCTTTCTCCCTGGAGGCTCAGCAAAACTCACGTGCACCTGAG
 TAGTCAGCACAGTACGTTACCATTGAATGGTATCAGCAACAGCCACTCA
 AGCCTCTAAGTATGTGATGGAGCTTAAGAAAGATGGAAGGCCAGTACA
 10 GGTGATGGGATTCTGATCGCTCTCTGGATCCAGCTGGTGTGATCG
 CTACCTTAGCATTCCAACATCCAGCCTGAAGATGAAGCAATATACTCT
 15 GTGGTGTGGGTGATACAATTAAATGAACAATTGTGATGTTTCGGCGGT
 GGAACCAAGGTCACTGTCTAGGT

mAb 7C9 heavy chain sequence: 358 bp

20 (SEQ ID No. 11)
 TGGGGCAGAGCCTGTGAAGCCAGGGGCTCAGTCAGTTGCTGCACAG
 CTTCTGGCTTCAACATTAAGACACCTATATGCACTGGTGAAGGAGAGG
 25 CCTGACAAGGGCTGGAGTGGATTGAGTCAGCAGCAGTGAATGGTAA
 TACTAAATGTGACTCGAGGTTTCAGGGCAAGGCCACTATAACAGCAGACA
 CATCCTTCAACAGCCTACCTGCAGCTCAGCAGCCTGACATCTGAGGAC
 30 ACTGCCGTCTATTACTGTGCTAGAAGGATCTACTTGGTAAGGGCTTG
 CTTTGGGCCAAGGCACCCTCTCACAGTCTCAGC AAAACACAG
 CCCCATCG

mAb 7C9 light chain sequence: 324 bp

(SEQ ID No. 12)
 40 TCCTCCCTGAGTGTGTCAGCAGGAGAGAAGGTCACTATGAGCTGCAAGTC
 CAGTCAGAGTCTGTTAACAGTGGAGATCAAAGAACTACTTGGCTGGT
 ACCAGCAGAAACCCAGGGCAGCCTCCTAAACTGTTGATCTACGGGCATCC
 ACTAGGGAAATCTGGGTCCCTGATCGCTTCACAGGAGTGGATCTGGAAC
 45 CGATTTCACTCTTACCATCAGCAGTGTGCAAGGCTGAGACCTGGCAGTT
 ATTACTGTGAGAATGATCAATTATCTCCACGTTGGTGTGATGGGACC
 AAGCTGGACCTGAAACAGGGCTGAT

mAb 7G4 heavy chain sequence: 367 bp

(SEQ ID No. 13)
 55 TGGAGGGGCTGGTACAGCCTGGGGTCTCTGAGACTCTCTGTGCAA
 CTTCTGGCTTCACTTACTGATCACTACATGGCTGGTCCGCCAGCCT
 CCAGGAAAGGCCTTGAGTGGGCTTTGTTAGATACAAAGCTAAGGG
 TTACACAAACAGAGTACACTGCATCTGTGAAGGGTCGTTCAACATCTCA
 60 GAGATAATTCCAAAGCATCTTCTATCTCAAATGAACACCCCTGAGAACT
 GAGGACAGTGCCACTTAACTGTGCAAGAGATAGAGGGGTTACGTGGG
 AGCTATGGACTACTGGGTCAGGAAACCTCAGTCACCGCTCCTCAGCCA
 65 AAACGACACCCCCATCT

mAb 7G4 light chain sequence: 321 bp

(SEQ ID No. 14)
CTCTCCCTGCCTGTCAGTCTGGAGATCAAGCCTCCATCTCTGCAGATC
TAGTCAGAGCCTGTACACAGGAATGGAAACACCTATTCCATTGGTACC
TGCAGAAGGCCAGGCCAGTCTCCAAAACCTCTGATCTACAAAGTTCCAAC
CGATTTCTGGGTCCCAGACAGGTTCAAGTGGCAGTGGATCAGGGACAGA
TTTCACACTCAAGATCAGCAGAGTGGAGGCTGAGGATCTGGAGTTATT
TCTGCTCTCAAAGTACACATGTTCCGTACACTTCGGAGGGGGACCAAG
CTGGAAATAAACAGGGCTGAT

mAb 10C8 heavy chain sequence: 352 bp

(SEQ ID No. 15)
TGGGGCAGAGCTGTGAGGTCAAGGGCCTCAGTCAGTTGCTCTGCACAT
CTTCTGGCTTCAACATTAAAGACTACTTCTACACTGGGTGAAACAGAGG
CCTGAAACAGGGCTGGAGTGGATTGGATGGATTGACCTTGAGAATGGTGA
TACTGAATATGCCCGAAGTCCAGGACAAGGCCACTATGACTGCAGACA
CATCCTCAACACAGCCTACCTGCACCTCAGCAGCCTGACATCTGAGGAC
ACTGGCGTCTATTACTGTAATGCAGATGGTAACTACGGGAAAGAACTACTG
GGGCCAAGGCACCACTCTCACCGTCTCAGCCAAAACAACAGCCCCAT
CG

mAb 10C8 light chain sequence: 324 bp

(SEQ ID No. 16)
CTCTCCCTGCCTGTCAGTCTGGAGATCAAGCCTCCATCTCTGCAGATC
TAGTCAGAGCCTGTACACAGTAATGGAAACACCTTTTACATTGGTACC
TGGAGAAGGCCAGGCCAGTCTCCAAAAGCTCTGATCTACAGAGTTCCAAC
CGATTTCTGGGTCCCAGACAGGTTCAAGTGGCAGTGGATCAGGGACAGA
TTTCACACTCAAGATCAGCAGAGTGGAGGCTGAGGATCTGGAGTTATT
TCTGCTCTCAAAGTACACATGTTCCCTCCGTACACGTTGGAGGGGGAC
AAGCTGGAAATAAACAGGGCTGAT

In another embodiment of the invention, one or more of the nucleic acid sequences described above encoding the antibody are subjected to humanization techniques or converted into chimeric human molecules for generating a variant antibody which has reduced immunogenicity in humans. Humanization techniques are well known in the art—see for example U.S. Pat. No. 6,309,636 and U.S. Pat. No. 6,407,213 which are incorporated herein by reference specifically for their disclosure on humanization techniques. Chimerics are also well known, see for example U.S. Pat. No. 6,461,824, U.S. Pat. No. 6,204,023, U.S. Pat. No. 6,020,153 and U.S. Pat. No. 6,120,767 which are similarly incorporated herein by reference.

In one embodiment of the invention, chimeric antibodies are prepared by preparing an expression vector which comprises a nucleic acid encoding a constant region domain of a human light or heavy chain genetically linked to a nucleic acid encoding a light chain variable region selected from the group consisting of 1H3-light (SEQ ID No. 2); 2G4-light

(SEQ ID No. 4); 4G7-light (SEQ ID No. 6); 5D2-light (SEQ ID No. 8); 5E6-light (SEQ ID No. 10); 7C9-light (SEQ ID No. 12); 7G4-light (SEQ ID No. 14) and 10C8-light (SEQ ID No. 16) or a heavy chain variable region selected from the group consisting of 1H3-heavy (SEQ ID No. 1); 2G4-heavy (SEQ ID No. 3); 4G7-heavy (SEQ ID No. 5); 5D2-heavy (SEQ ID No. 7), 5E6-heavy (SEQ ID No. 9), 7C9-heavy (SEQ ID No. 11), 7G4-heavy (SEQ ID No. 13) and 10C8-heavy (SEQ ID No. 15). It is of note that all of these sequences are described above.

In another embodiment of the invention, there are provided recombinant antibodies comprising at least one modified variable region, said region selected from the group consisting of 1H3-light (SEQ ID No. 2); 2G4-light (SEQ ID No. 4); 4G7-light (SEQ ID No. 6); 5D2-light (SEQ ID No. 8); 5E6-light (SEQ ID No. 10); 7C9-light (SEQ ID No. 12); 7G4-light (SEQ ID No. 14), 10C8-light (SEQ ID No. 16), 1H3-heavy (SEQ ID No. 1); 2G4-heavy (SEQ ID No. 3); 4G7-heavy (SEQ ID No. 5); 5D2-heavy (SEQ ID No. 7), 5E6-heavy (SEQ ID No. 9), 7C9-heavy (SEQ ID No. 11), 7G4-heavy (SEQ ID No. 13) and 10C8-heavy (SEQ ID No. 15), in which at least one but fewer than about 30 of the amino acid residues of said variable region has been changed or deleted without disrupting antigen binding. It is of note that all of these sequences are described above.

In yet other embodiments, immunoreactive fragments of any of the above-described monoclonal antibodies, chimeric antibodies or humanized antibodies are prepared using means known in the art, for example, by preparing nested deletions using enzymatic degradation or convenient restriction enzymes.

It is of note that in all embodiments describing preparation of humanized antibodies, chimeric antibodies or immunoreactive fragments of monoclonal antibodies, these antibodies are screened to ensure that antigen binding has not been disrupted. This may be accomplished by any of a variety of means known in the art, but one convenient method would involve use of a phage display library. As will be appreciated by one of skill in the art, as used herein, ‘immunoreactive fragment’ refers in this context to an antibody fragment reduced in length compared to the wild-type or parent antibody which retains an acceptable degree or percentage of binding activity to the target antigen. As will be appreciated by one of skill in the art, what is an acceptable degree will depend on the intended use.

It is of note that as discussed herein, any of the above-described antibody or humanized variant thereof may be formulated into a pharmaceutical treatment for providing passive immunity for individuals suspected of or at risk of developing hemorrhagic fever comprising a therapeutically effective amount of said antibody. The pharmaceutical preparation may include a suitable excipient or carrier. See, for example, Remington: *The Science and Practice of Pharmacy*, 1995, Gennaro ed. As will be apparent to one knowledgeable in the art, the total dosage will vary according to the weight, health and circumstances of the individual as well as the efficacy of the antibody.

While the preferred embodiments of the invention have been described above, it will be recognized and understood that various modifications may be made therein, and the appended claims are intended to cover all such modifications which may fall within the spirit and scope of the invention.

TABLE 1

Dose-dependent protective efficacy of McAbs in mice			
Treatment ^a	Dose (μg/treatment)	Meantime to death ^b	No. of survivors/total
McAb 4G7	100	7.00 (n = 1)	5/6
	50	7.00 (n = 1)	5/6
	25	6.00 (n = 3)	3/6
	12.5	6.80 (n = 5)	1/6
	6.25	8.20 (n = 5)	2/6
McAb 5D2	100	N/A ^c	6/6
	50	N/A ^c	6/6
	25	N/A ^c	6/6
	12.5	N/A ^c	6/6
	6.25	7.50 (n = 2)	4/6
McAb 5E6	100	N/A ^c	6/6
	50	N/A ^c	6/6
	25	N/A ^c	6/6
	12.5	6.50 (n = 2)	4/6
	6.25	6.67 (n = 3)	3/6
McAb 7C9	100	N/A ^c	6/6
	50	N/A ^c	6/6
	25	7.00 (n = 1)	5/6
	12.5	7.00 (n = 1)	5/6
	6.25	6.50 (n = 4)	2/6
McAb 7G4	100	N/A ^c	6/6
	50	7.50 (n = 1)	4/6
	25	7.00 (n = 1)	5/6
	12.5	7.60 (n = 5)	1/6
	6.25	6.60 (n = 5)	1/6
McAb 10C8	100	7.00 (n = 1)	5/6
	50	7.00 (n = 1)	5/6
	25	7.50 (n = 4)	2/6
	12.5	7.00 (n = 5)	1/6
	6.25	6.40 (n = 5)	1/6
PBS		5.80 (n = 5)	0/5

^aMice were intraperitoneally treated with antibodies 1 day after challenge with 1000 LD₅₀ of the mouse-adapted Ebola virus.^bData for animals that died (numbers of animals are shown in parentheses).^cN/A: not applicable.

TABLE 2

Time dependency of the protective efficacy of Mabs in mice			
Mabs	Day of treatment ^a	Mean time to death ^b	No. of survivors/total
1H3 100 μg	-4	6.70 ± 0.61 (n = 10)	0/10
	-1	6.60 ± 0.61 (n = 10)	0/15
	+1	8.10 ± 0.74 (n = 9)	6/15
	+2	6.60 ± 0.80 (n = 5)	5/10
	+3	6.40 ± 0.97 (n = 10)	0/10
2G4 100 μg	-4	7.40 ± 0.63 (n = 10)	0/10
	-1	7.86 ± 0.74 (n = 14)	1/15
	+1	8.00 (n = 6)	9/15
	+2	7.30 ± 0.47 (n = 3)	7/10
	+3	5.70 ± 1.13 (n = 10)	0/10
4G7 100 μg	-4	7.42 ± 0.46 (n = 7)	3/10
	-1	7.08 ± 0.74 (n = 14)	1/15
	+1	8.25 ± 0.43 (n = 4)	11/15
	+2	n/a ^c	10/10
	+3	5.67 ± 1.34 (n = 9)	1/10
5D2 100 μg	-4	7.00 (n = 1)	9/10
	-1	8.00 ± 1.00 (n = 2)	13/15
	+1	n/a	15/15
	+2	7.00 (n = 4)	6/10
	+3	6.30 ± 1.05 (n = 10)	0/10
5E6 100 μg	-4	7.00 (n = 2)	8/10
	-1	8.25 ± 0.43 (n = 4)	11/15
	+1	7.00 (n = 1)	14/15
	+2	6.00 (n = 1)	9/10
	+3	5.80 ± 1.03 (n = 10)	0/10
7C9 100 μg	-4	7.00 (n = 1)	9/10
	-1	7.75 ± 0.43 (n = 4)	11/15
	+1	8.00 ± 0.82 (n = 3)	12/15
	+2	7.00 (n = 1)	9/10
	+3	6.10 ± 0.67 (n = 10)	0/10
7G4	-4	8.20 ± 0.71 (n = 10)	0/10

TABLE 2-continued

Time dependency of the protective efficacy of Mabs in mice				
5	Mabs	Day of treatment ^a	Mean time to death ^b	No. of survivors/total
10C8 100 μg	100 μg	-1	8.07 ± 0.59 (n = 14)	1/15
		+1	n/a	15/15
		+2	7.10 ± 0.57 (n = 9)	1/10
		+3	6.70 ± 0.44 (n = 10)	0/10
	10C8	-4	7.83 ± 0.64 (n = 6)	4/10
17F8 ^d 100 μg	100 μg	-1	7.64 ± 1.17 (n = 14)	1/15
		+1	8.50 ± 0.50 (n = 2)	13/15
		+2	6.83 ± 0.37 (n = 6)	4/10
		+3	6.30 ± 1.13 (n = 10)	0/10
	17F8 ^d	-4	6.00 ± 1.10 (n = 9)	1/10
PBS	100 μg	-1	6.13 ± 0.88 (n = 15)	0/15
		+1	7.21 ± 0.86 (n = 14)	1/15
		+2	6.10 ± 0.83 (n = 10)	0/10
		+3	6.00 ± 1.13 (n = 10)	0/10
	PBS	-4	5.40 ± 1.43 (n = 10)	0/10
20		-1	6.60 ± 0.80 (n = 5)	0/5
		+3	5.00 ± 0.60 (n = 10)	0/10

^aMice were intraperitoneally treated with each MAb at indicated time before or after challenge with 1000 LD₅₀ of the mouse-adapted Ebola virus.^bData for animals that died (numbers of animals are shown in parentheses).^cN/A: not applicable.^dControl Mab: anti-MAR GP.

TABLE 3

Protective efficacy of Mabs in guinea pigs				
30	Treatment	Day of treatment ^a	Meantime to death ^b	No. of survival/Total ^c
	Cocktail of 5D2(3 mg) + 4G7(2 mg) + 1H3(1 mg) + 2G4(1 mg)	1	N/A ^d	6/6
		2		
	Cocktail of 5E6(3 mg) + 4G7(2 mg) + 1H3(1 mg) + 2G4(1 mg)	1	N/A	6/6
35		2		
	Cocktail of 7C9(3 mg) + 4G7(2 mg) + 1H3(1 mg) + 2G4(1 mg)	1	N/A	6/6
		2		
	Cocktail of 7G4(3 mg) + 4G7(2 mg) + 1H3(1 mg) + 2G4(1 mg)	1	N/A	6/6
40		2		
	Cocktail of 10C8(3 mg) + 4G7(2 mg) + 1H3(1 mg) + 2G4(1 mg)	1	9.00 (n = 1)	5/6
		2		
	Cocktail of PBS + PBS	1	7.00 (n = 6)	0/6
		2		

^aGuinea pigs were intraperitoneally treated with the Mabs as showed dose in the table on the indicated days after challenge with 1000 LD₅₀ of the guinea pig-adapted Ebola virus.^bData for all animals that died (numbers of animals are shown in parentheses).^cSurvival rate on day 28 after challenge.^dN/A: not applicable.

TABLE 4

55	McAb Isotype	eVLPs	Antigen				
			eGP1,2	sGP	1-295aa	157-369aa	Rf-GP1
	1H3	IgG2a,κ	+	+	+	-	-
	2G4	IgG2b,κ	+	+	-	-	-
	4G7	IgG2a,κ	+	+	-	-	-
	5D2	IgG2a,κ	+	+	-	+	+
	5E6	IgG2a,λ	+	+	-	-	+
	7C9	IgG2a,κ	+	+	-	±	+
	7G4	IgG1,κ	+	+	-	-	+
	10C8	IgG2a,κ	+	+	-	-	+

^aAntigens (0.3 μg/well) were coated in 96 well microtiter plate then blocking with 2% skim milk. Serial dilutions of each MAb were applied to the plate followed by HRP-conjugated goat anti-mouse IgG. After incubation with substrate, the absorbance was read at OD405. Cut off was 2X background.

US 9,249,214 B2

11
TABLE 5

Prolonged survival seen in McAb-treated Guinea pigs		
Treatment ^a	Mean time to death ^b	Student's t-test
MAb 1H3	11.7 ± 2.18 (n = 5)	p = 0.0181
MAb 2G4	11.5 ± 1.50 (n = 2)	N/A ^c
MAb 4G7	10.5 ± 1.50 (n = 2)	N/A ^c
MAb 5D2	9.4 ± 1.02 (n = 5)	p = 0.0244
MAb 5E6	10.8 ± 1.47 (n = 5)	p = 0.0092
Mab 7C9	9.6 ± 0.80 (n = 5)	p = 0.0056
MAb 7G4	9.6 ± 0.80 (n = 5)	p = 0.0056
Mab 10C8	9.4 ± 1.20 (n = 5)	p = 0.0428
PBS	7.67 ± 0.75 (n = 6)	N/A ^c

^aGuinea pigs were intraperitoneally treated with 5 mg of the MAb as showed in the table on day 1 after challenge with 1000 LD₅₀ of the guinea pig-adapted Ebola virus.

^bData for all animals that died (numbers of animals are shown in parentheses).

^cN/A: not applicable.

12
TABLE 6

Protective efficacy of MAbs in guinea pigs				
		Treatment	Day of treatment ^a	Meantime to death ^b
10	Cocktail of 4G7(2 mg) + 1H3(1.5 mg) + 2G4(1.5 mg)	-1	11.17 ± 3.09 (n = 3)	3/6
	Cocktail of 4G7(2 mg) + 1H3(1.5 mg) + 2G4(1.5 mg)	+1	7.92 ± 0.42 (n = 3)	3/6
	Cocktail of 4G7(2 mg) + 1H3(1.5 mg) + 2G4(1.5 mg)	+2	N/A ^d	6/6
	Cocktail of 4G7(2 mg) + 1H3(1.5 mg) + 2G4(1.5 mg)	+3	11.17 ± 3.09 (n = 3)	4/6
	PBS	+2	6.58 ± 0.59 (n = 6)	3/6

^aGuinea pigs were intraperitoneally treated with the MAbs as showed dose in the table on the indicated days before or after challenge with 1000 LD₅₀ of the guinea pig-adapted Ebola virus.

^bData for all animals that died (numbers of animals are shown in parentheses).

^cSurvival rate on day 28 after challenge.

^dN/A: not applicable.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 21

<210> SEQ ID NO 1
<211> LENGTH: 373
<212> TYPE: DNA
<213> ORGANISM: mouse

<400> SEQUENCE: 1

```
tggggcagag cttgtgaagc caggggcotc agtcaagttg tcctgcacag ctttgtggctt      60
caacataaaa gacacctata tacattgggt gaaacagggg cctgaacagg gcctggagtg      120
gatttggaaagg attgatcctg cgaatggtaa tactaaatat gaccggaaatg tccaggggcaa      180
ggccactatac acagcagaca catcctccaa tacagectac ctgcagctca gcccgcctgac      240
atctgaggac actgcgcgtct attactgtgc tagggagtcg aggataatcta ctatgcttac      300
gacggggtagt tttgactact gggggccaagg caccactctc acagtctctt cagccaaaac      360
aacagccccca tcg                                         373
```

<210> SEQ ID NO 2
<211> LENGTH: 303
<212> TYPE: DNA
<213> ORGANISM: mouse

<400> SEQUENCE: 2

```
gcaatcatgt ctgcatctcc aggggagaag gtcaccatga cctgcagtgc cagctcaagt      60
gtaagttaca tqtactggta ccagcagaag ccaggatctt ccccccacact cctgtattat      120
gacacatcca acctggcttc tggagtcctt gttcgttca gtggcagtgg gtctgggacc      180
tcttactctc tcacaatcag ccgaatggag gctgaagatg ctgccactta ttactgccag      240
cagttggatgta gttacccgtt cacgttcgga ggggggacca agctggaaat aaaacgggct      300
gat                                         303
```

<210> SEQ ID NO 3
<211> LENGTH: 364
<212> TYPE: DNA
<213> ORGANISM: mouse

<400> SEQUENCE: 3

```
tggaggaggc ttgatgcaac ctggaggatc catgaaactc tcctgtgttg cctcaggatt      60
```

-continued

cactttcagt aactactgga tgaactgggt ccgccagtc ctccatcaaaagg ggcttgagt	120
ggtttgttcaa atttagattga aatctaataa ttatgcacaca cattatgcgg agtctgtgaa	180
agggaggttc accatttcaa gagatgattc caaaaagggt gtctacctgc aaatgaatac	240
cttaagagct gaagacactg gcatttatta ctgtacccgg gggaaatggta actacaggc	300
tatggactac tgggtcaag gaacctcagt caccgtctcc tcagccaaa caacacccc	360
atca	364

<210> SEQ ID NO 4
<211> LENGTH: 306
<212> TYPE: DNA
<213> ORGANISM: mouse

<400> SEQUENCE: 4

gcctccctat ctgttatctgt gggagaaact gtctccatca catgtcgagc aagtgagaat	60
atttacatgt gtttagcatg gtatcagcag aaacaggaa aatctcctca gctcctggtc	120
tattctgaa caatcttagc agatggtgc ccatcaaggt tcagtgccag tggatcaggc	180
actcagttt ccctcaagat caacagcctg cagtctgaag atttgggac ttattactgt	240
caacatttt ggggtactcc gtacacgttc ggaggggggg acaagctgga aataaaacgg	300
gctgat	306

<210> SEQ ID NO 5
<211> LENGTH: 358
<212> TYPE: DNA
<213> ORGANISM: mouse

<400> SEQUENCE: 5

tggacctgag ctggagatgc ctggcgcttc agtgaagata tcctgcaagg cttctgggt	60
cttcattcaat ggcttcagta tgaactgggt gaagcagcag aatggaaaga gccttggatg	120
gattggaaat attgatactt attatgggtg tactacctac aaccagaaat tcaagggca	180
ggccacattg actgtggaca aatctccag cacagcctac atgcagctca agagectgac	240
atctgaggac tctgcagttt attactgtgc aagatcgcc tactacggta gtactttgc	300
ttactggggc caagggactc tggtcactgt ctctgcagcc aaaacaacag ccccatcg	358

<210> SEQ ID NO 6
<211> LENGTH: 306
<212> TYPE: DNA
<213> ORGANISM: mouse

<400> SEQUENCE: 6

gcctccctat ctgcattctgt gggagaaact gtcaccatca catgtcgagc aagtgagaat	60
atttacatgtt atttagcatg gtatcagcag aaacaggaa aatctcctca gctcctggtc	120
tataatgcacca aaacatataat agaggggtgtg ccatcaaggt tcagtgccag tggatcaggc	180
acacatgtttt ctctgaagat caacagcctg cagcctgaag atttgggag ttattctgt	240
caacatcattt ttgggtactcc attcacatcc gggtcgaaaa cagatggta aataaaacgg	300
gctgat	306

<210> SEQ ID NO 7
<211> LENGTH: 340
<212> TYPE: DNA
<213> ORGANISM: mouse

-continued

<400> SEQUENCE: 7

gggacctggc ctggtgagac cttctcagtc tctgtccctc acctgcactg tcactggcta	60
ctcaatcacc agtgattatg cctggaaactg gatccggcag tttccaggaa acaaactgga	120
gtggctggc tatataacca acactggtag cactggcttc aaccatctc tcaaaagtgc	180
aatctctatc actcgagaca catccaagaa ccagtttctc ctgcagttga tttctgtgac	240
tactgaggac acageccacat atcactgtgc aaggggctt gcttaactggg gccaaaggac	300
tctggtcaact gtctctgcag ccaaaacaac agccccatcg	340

<210> SEQ ID NO 8

<211> LENGTH: 321

<212> TYPE: DNA

<213> ORGANISM: mouse

<400> SEQUENCE: 8

ctcactttgt cggttaccat tggacaacca gcctccatct cttgcaagtc aagtcagagc	60
ctcttagata gtgatggaaa gacatatctg aattggtgt tacagaggcc aggccagtc	120
ccaaaggccc taatctatct ggtgtctaaa ctggactctg gagttcaactga caggttca	180
ggcagtggtt cagggacaga tttcacactg aaaatcagca gagtgaggcc tgaggattt	240
ggagtttatt attgttggca aggtacacac tctccattca cgttcggctc gggcacaaag	300
ttggaaataa aacgggctga t	321

<210> SEQ ID NO 9

<211> LENGTH: 370

<212> TYPE: DNA

<213> ORGANISM: mouse

<400> SEQUENCE: 9

tgggggaggc ttatgtgaagc ctggagggtc cctgaaactc tcctgtgcag cctctggatc	60
cgttttcaatc agatatgaca tgtctgggt tcgccagact ccggagaaga ggctggagt	120
ggtcgcatac attagtcgtg gtgggggtt catctactat ccagacactg tgaagggccg	180
attcaccatc tccagagaca atgccaagaa caccctgtac ctgcaaatga gcagtctgaa	240
gtctgacgac acagccatgt attactgtgc aagacacgt tactacggta gtatccccct	300
ctatgtatg gactactggg gtcaaggaac ctcagtcacc gtctctcag ccaaaacaac	360
agccccatcg	370

<210> SEQ ID NO 10

<211> LENGTH: 324

<212> TYPE: DNA

<213> ORGANISM: mouse

<400> SEQUENCE: 10

ttagccttct tctccctggg agcctcagca aaactcacgt gcacccctgag tagtcagcac	60
agtagcttca ccatgaaatg gtatcagca cagccactca agcctctaa gtatgtatg	120
gagcttaaga aagatggaaag ccacagtaca ggtgatggg ttcctgatcg cttctctgga	180
tccagctctg gtgctgatcg ctaccttagc atttccaaca tccagcgtga agatgaagca	240
atatacatct gtgggttggg tgataacaatt aatgaacaat ttgtgtatgt tttcggcggt	300
ggaaccaagg tcactgttctt aggt	324

<210> SEQ ID NO 11

<211> LENGTH: 358

-continued

<212> TYPE: DNA
 <213> ORGANISM: mouse

<400> SEQUENCE: 11

```
tggggcagag cttgtgaagc caggggcctc agtcaagtgg tccgtcacag cttctggctt      60
caacattaaa gacacccata tgcactgggt gaaggagagg cctgacaagg gcctggagtg      120
gattgaaagg attgatccag cgaatggta tactaaatgt gactcgaggt ttcaggcga      180
ggccactata acacgacaca catcctccaa cacagcctac ctgcagctca gcagectgac      240
atctgaggac actgcgtctt attactgtgc tagaaggata tactttggta agggcttga      300
cttttggggc caaggcacca ctctcacagt ctctcagcc aaaacaacag ccccatcg      358
```

<210> SEQ ID NO 12

<211> LENGTH: 324
 <212> TYPE: DNA
 <213> ORGANISM: mouse

<400> SEQUENCE: 12

```
tccctccotga gtgtgtcagc aggagagaag gtcactatga gtcgtcaagtc cagtcagagt      60
ctgtttaaca gtggagatca aaagaactac ttggcctggt accagcagaa accagggcag      120
cctcctaaac tttgtatcta cggggcatcc actaggaaat ctggggtccc tgatcgctc      180
acaggcagtg gatctggAAC cgatttcact cttaccatca gcaatgtgca ggctgaagac      240
ctggcagttt attactgtca gaatgtcaa ttttatcttc ccacgttccg tgatggacc      300
aagctggacc tgaaacgggc tgat                                324
```

<210> SEQ ID NO 13

<211> LENGTH: 367
 <212> TYPE: DNA
 <213> ORGANISM: mouse

<400> SEQUENCE: 13

```
tggagggggc ttggtagcgc ctgggggttc tctgagactc tcctgtgcaaa cttctggctt      60
cacctttact gatcactaca tgggtgggt cggccagcc tcaggaaagg cacttgagtg      120
gttgggtttt gtttagataca aagctaaggg ttacacaaca gagtacactg catctgtgaa      180
gggtcggttc accatctcca gagataattc ccaaagcatc ctctatctc aaatgaacac      240
cctgagaact gaggacagtg ccacttatta ctgtgcaaga gatagaggg gttacgtgg      300
agctatggac tactggggc aaggAACCTC agtcaccgtc tcctcagccaa aacgacacc      360
ccccatct                                367
```

<210> SEQ ID NO 14

<211> LENGTH: 321
 <212> TYPE: DNA
 <213> ORGANISM: mouse

<400> SEQUENCE: 14

```
ctctccctgc ctgtcagtct tggagatcaa gcctccatct ctgcagatc tagtcagagc      60
cttgtacaca ggaatggaaa cacctatttc cattggtacc tgcagaagcc aggccagtct      120
ccaaaactcc ttagtacaaa agtttccaaac cgattttctg gggtcccaga caggttcagt      180
ggcagtggat cagggacaga tttcacactc aagatcagca gagtggaggc tgaggatctg      240
ggagtttatt tctgtctca aagtacacat gttccgtaca ctttcggagg ggggaccaag      300
ctggaaataa aacgggctga t                                321
```

-continued

<210> SEQ ID NO 15
<211> LENGTH: 352
<212> TYPE: DNA
<213> ORGANISM: mouse

<400> SEQUENCE: 15

tggggcagag	cttgcaggat	caggggcctc	agtcaagttg	tcctgcacat	cttctggctt	60
caacattaaa	gactacttcc	tacactgggt	gaaacagagg	cctgaacagg	gcctggagtg	120
gattggatgg	attgatcctg	agaatggtga	tactgaatat	gccccgaagt	tccaggacaa	180
ggccactatg	actgcagaca	catactccaa	cacagcctac	ctgcacacctca	gcagcctgac	240
atctgaggac	actggcgctc	attactgtaa	tgcagatgg	aactacggga	agaactactg	300
gggccaaggc	accactctca	ccgtctccctc	agccaaaaca	acagccccat	cg	352

<210> SEQ ID NO 16
<211> LENGTH: 324
<212> TYPE: DNA
<213> ORGANISM: mouse

<400> SEQUENCE: 16

ctctccctgc	ctgtcagtc	tggagatcaa	gcctccatct	cttgcagatc	tagtcagagc	60
cttgcacaca	gtaatggaaa	cacctttta	cattggtacc	tgcagaagcc	aggccagtct	120
ccaaagctcc	tgtatctacag	agtttccaaac	cgattttctg	gggtcccaga	caggttcagt	180
ggcagtggat	caggcacaga	tttccacactc	aagatcagca	gagtggaggc	tgaggatctg	240
ggagtttatt	tctgctctca	aagtacacat	gttcctccgt	acacgttcgg	aggggggacc	300
aagctggaaa	aaaaacgggc	tcat				324

<210> SEQ ID NO 17
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: mouse

<400> SEQUENCE: 17

Ser	Asn	Thr	Thr	Gly	Lys	Leu	Ile	Trp	Lys	Val	Asn	Pro	Glu	Ile
1					5				10				15	

<210> SEQ ID NO 18
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: mouse

<400> SEQUENCE: 18

Arg	Glu	Ala	Ile	Val	Asn	Ala	Gln	Pro	Lys	Cys	Asn	Pro	Asn	Leu
1					5				10				15	

<210> SEQ ID NO 19
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: mouse

<400> SEQUENCE: 19

Arg	Glu	Ala	Ile	Val	Asn	Ala	Gln	Pro	Lys	Cys	Asn	Pro	Asn	Leu
1					5				10				15	

<210> SEQ ID NO 20
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: mouse

-continued

<400> SEQUENCE: 20

Asp	Pro	Gly	Thr	Asn	Thr	Thr	Thr	Glu	Asp	His	Lys	Ile	Met	Ala
1														15
5 10														

<210> SEQ ID NO 21

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: mouse

<400> SEQUENCE: 21

Ala	Thr	Gln	Val	Glu	Gln	His	His	Arg	Arg	Thr	Asp	Asn	Asp	Ser
1														15
5 10														

The invention claimed is:

1. A monoclonal antibody that binds Ebola glycoprotein comprising a light chain variable region comprising the amino acid sequence deduced from the nucleic acid molecule as set forth in SEQ ID NO:4 and a heavy chain variable region comprising the amino acid sequence deduced from the nucleic acid molecule as set forth in SEQ ID NO:3.

2. A method of preparing a chimeric antibody that binds Ebola glycoprotein comprising:

providing an expression vector comprising a nucleic acid molecule encoding a constant region domain of a human light chain genetically linked to a nucleic acid molecule encoding a light chain variable region comprising the nucleic acid molecule as set forth in SEQ ID No: 4; and

providing an expression vector comprising a nucleic acid molecule encoding a constant region domain of a human heavy chain genetically linked to a nucleic acid molecule encoding a heavy chain variable region comprising the amino acid sequence deduced from the nucleic acid molecule as set forth in SEQ ID No.3;

20

30

35

expressing the expression vectors in a suitable host; and recovering the chimeric antibody that binds Ebola glycoprotein from said host.

3. A method of preparing a chimeric antibody that binds Ebola glycoprotein comprising:

providing an expression vector comprising a nucleic acid molecule encoding a constant region domain of a human light chain genetically linked to a nucleic acid molecule encoding a light chain variable region comprising the nucleic acid molecule as set forth in SEQ ID No:4; and a nucleic acid molecule encoding a constant region domain of a human heavy chain genetically linked to a nucleic acid molecule encoding a heavy chain variable region comprising the amino acid sequence deduced from the nucleic acid molecule as set forth in SEQ ID No:3;

expressing the expression vector in a suitable host; and recovering the chimeric antibody that binds Ebola glycoprotein from said host.

4. A pharmaceutical composition comprising the monoclonal antibody of claim 1 and a pharmaceutically acceptable excipient or carrier.

* * * * *